Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1206

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy
The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into:
• Riluzole
• Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into:
• Hospital Pharmacies
• Retail & Online Pharmacies
North America is expected to hold a dominant position in the market, increasing focus of manufacturers on novel drug development for ALS
North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment market, as major companies present in the region are focusing on collaborations for product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for treatment of ALS.

Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1206

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]